

Key Information Document

Purpose

This document provides you with the key information about this investment product. It is not marketing material. We are required to provide you this information by law in order to help you understand the nature, risks and costs of this product along with the potential gains and losses that an investor in this product might make, to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand.

Product

The product this document relates to is the **Ordinary Share class (“the Investment”) in the Seneca Growth Capital VCT Plc (“the VCT”) when purchased on the open market.** The manufacturer of this product is Seneca Growth Capital VCT Plc, 9 The Parks, Haydock, Cheshire, WA12 0JQ. The Manager of this product is Seneca Partners Ltd (“Seneca”), 9 The Parks, Haydock, Cheshire, WA12 0JQ. Seneca Partners Ltd is authorised and regulated by the Financial Conduct Authority. The Manager has delegated management of the Ordinary Share class to those members of the board who comprised the Board of Directors of the VCT prior to the launch of the New B Share class. (Please note that the B Share class does not form a part of the Investment). You can contact Seneca by email at clientteam@senecapartners.co.uk, by telephone on 01942 271746, or at the address shown above. Seneca’s website can be found at www.senecapartners.co.uk.

This document was produced on 30th November 2020.

What is this product?


The product is an Alternative Investment Fund in the form of a Venture Capital Trust. The Investment comprises the Ordinary Share class issued by Seneca Growth Capital VCT Plc. These shares are listed on the premium segment of the Official List of the UKLA and can be traded on the Main Market of the London Stock Exchange.

Currently, the Ordinary Shares cannot be purchased from the VCT directly and are only available on the open market. The VCT holds a portfolio of equity shares in small companies in the UK Medtech sector for the benefit of the Ordinary Shareholders. The companies in this portfolio are either quoted on the AIM market or unquoted.

The intended investor will be those individuals seeking to receive tax free income and long term capital growth in a tax efficient manner, from a diverse portfolio of higher risk investments in the UK Medtech sector. **Please note that whilst any dividends paid on shares purchased on the open market are unlikely to be subject to Dividend Tax, the purchase of such shares will not qualify for any Income Tax relief (unlike new shares issued in a VCT).**

What are the risks and what could I get in return?

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. The Summary Risk Indicator for this product is as follows:



The following table shows the money you could get back over the next five years, under different scenarios, assuming that you invest £10,000 by buying shares on the open market and that the purchase price on the open market remains at a discount of c. 12% to the Net Asset Value per share. The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products.

		1 Year	3 Years	5 Years
Stress scenario	What you might get back after costs	£8,282.79	£5,443.12	£3,459.64
	Average return each year	-17.17%	-18.35%	-19.13%
Unfavourable scenario	What you might get back after costs	£9,455.71	£8,177.50	£6,544.98
	Average return each year	-5.44%	-6.49%	-8.13%
Moderate scenario	What you might get back after costs	£10,576.42	£11,521.18	£10,759.16
	Average return each year	5.76%	4.83%	1.47%
Favourable scenario	What you might get back after costs	£11,959.11	£16,760.10	£20,220.52
	Average return each year	19.59%	18.78%	15.12%

This product cannot be easily cashed in. This means it is difficult to estimate how much you would get back if you cash in before the end of the recommended holding period. You will either be unable to cash in early or you may have to pay high costs or make a large loss if you do so. Your maximum loss would be that you will lose all your investment.

The scenarios presented are an estimate of future performance and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the investment/product. The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you.

The figures shown include all the costs of the product itself, but do not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation and exclude any tax reliefs you may be entitled to. Your maximum loss would be that you will lose all your investment. You are unlikely to be able to claim loss relief on a proportion of any losses made.

What happens if Seneca Growth Capital VCT Plc is unable to pay out?

As a shareholder in the VCT you would not be able to make a claim to the Financial Services Compensation Scheme about the VCT in the event that the VCT is unable to pay out. You may face a financial loss should the Company default on its obligations.

There is no compensation or guarantee scheme in place which may offset all, or any, of this loss.

What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

At any given time, the price at which you can buy shares on the open market (the "offer price") is usually higher than the price at which you can sell shares on the open market (the "bid price"). As at 30th November 2020, the difference (the "bid-offer spread") for the Investment was 8p per share.

The person or firm selling you or advising you about this product may charge you other costs (including the bid-offer spread). If so, this person or firm will provide you with information about these costs and show you the impact that all costs will have on your investment over time.

1. Costs over time

The following are investment scenarios based on an investment of £10,000, showing the total costs that may be incurred in each time period shown. Where a range of example costs has been given, the lower amounts relate to the total costs that may be incurred in the "stress scenario" in the table towards the top of this page and the higher amounts those that may be incurred in the "favourable scenario".

		After 1 Year	After 3 Years	After 5 Years
If you cash in your investment	Total costs	£126.13 to £182.12	£502.82 to £1,137.23	£744.73 to £6,161.86
	Impact on return (RIY) per year	1.26% to 1.82%	2.44% to 2.63%	3.22% to 6.29%

2. Composition of costs

The following shows the impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period and the meaning of the different cost categories.

One-off costs	Initial Fee	0% p.a. When buying shares on the open market, there is a bid/offer spread. On 30/11/2020, this was 8p per share.	The bid/offer spread is the difference between the price you would have been offered when buying or selling shares on the open market.
Ongoing costs	Running costs of the Company (including Annual Management Charge)	0% p.a. until June 2021 up to 3.0% p.a. thereafter (inclusive of any AMC)	The impact of the costs that accrue each year for running the Company in which you are invested.
Incidental costs	Performance fee	25% (reducing to 10%)	The impact of the Performance Fee. There will be no performance fee on the first 14.75p of dividends received per share from 30/11/2020. The next 34.6p of dividends will be subject to a 25% Performance Fee. A 10% fee will apply to any dividends that exceed that, subject to a 6% p.a. hurdle.

How long should I hold it and can I take money out early?

You should expect to hold your shares for more than 5 years, as VCTs are intended to have a long investment horizon. The Investment should be considered as a long-term investment.

Neither the VCT nor the Investment have a fixed winding up date and therefore, unless shareholders have voted to wind-up the VCT or Investment, Shareholders will only be able to realise their investment through the open market. You may sell your investments within the recommended holding period without penalty fee.

The Investment's share prices are quoted on the London Stock Exchange so, provided there is a willing buyer, you may realise your investment through a stockbroker or share dealing account. Previously owned VCT shares do not qualify for initial income tax relief and there is, therefore, a limited market for secondary VCT shares. The price you receive on the open market may therefore not reflect the underlying net asset value of the shares. The secondary market for VCT shares is generally illiquid and Shareholders may find it difficult to realise their investment.

The VCT does not offer a share buyback policy.

How can I complain?

The Manager has established procedures in accordance with the FCA Rules for consideration of complaints. Details of these procedures are available from it on request. If you wish to make a formal complaint, you should contact **The Complaints Officer, Seneca Partners Ltd, 9 The Parks, Haydock, WA12 0JQ.**

If you are unhappy with the way in which we handle your complaint or the outcome, as a shareholder of Seneca Growth Capital VCT Plc you may not have the right to ask the Financial Ombudsman Service to carry out an independent review of your complaint. Their contact details are **The Financial Ombudsman Service, Exchange Tower, London, E14 9SR.** Their phone numbers are 0300 123 9123 (charged at a national rate) or 0800 023 4567 (free from landlines). You can send an e-mail to: complaint.info@financial-ombudsman.org.uk or you can log on to their website: www.financial-ombudsman.org.uk.

Who should I contact if I have any queries?

This is a high risk investment and we recommend that you seek advice from a qualified financial adviser before making an investment of this type. If you have any queries, please speak to your financial adviser. Alternatively, you can contact our Client Relationship Team on 01942 271746 but please note that we are unable to give financial or taxation advice.